Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Immune Network Research ( IMM-V ) -- Ignore unavailable to you. Want to Upgrade?

To: John Fairchild who wrote (53)	7/20/1998 11:06:00 PM
From: John Fairchild	Read Replies (1) \| Respond to of 57

Immune Network Research Ltd - Appointment; HIV study progress Immune Network Research Ltd IMMShares issued 19,970,4521998-07-20 close $0.16Monday Jul 20 1998VANCOUVER, B.C. (July 20, 1998) - Victor Jones, President, is very pleased to announce the appointment of Brian Conway MD, FRCPC to the Scientific Advisory Board of the Company. Dr. Conway is one of the leading experts in the field of HIV virology, and has published over 40 articles in peer reviewed journals in the field since completing a specialty in infectious disease at the University of Manitoba in 1988. He has been the recipient of a number of industrial and academic grants for the study of antiviral therapies and the virology of HIV infection. His research interest and expertise in HIV therapies and the measurement of the efficacy of therapy make him uniquely qualified to participate in the development of novel immune-based strategies to control HIV in infected patients. Dr. Conway has recently moved to Viridae Clinical Sciences Inc. in Vancouver as its Medical Director, joining Dr. Steven Sacks, its CEO to establish a comprehensive laboratory and clinical virology research program in the fields of herpes, hepatitis and HIV. Viridae is an integrated virology research organization which has the infrastructure to develop new studies of promising antiviral compounds from initial inception to their approval by regulatory authorities. Dr. Conway remains on staff at the University of British Columbia as an Assistant Professor in the Department of Pharmacology and Therapeutics. Dr. Conway joins Dr. Michael Grant (Memorial University), Dr. Heinz Kohler (University of Kentucky) and Dr. Ken Rosenthal (McMaster University) on the Scientific Advisory Board of the Company to assist with plans for clinical trials of its proprietary monoclonal antibody 1F7 and review of new projects to expand on its core technology. The Company is on day 105 of a six month study of the effects on the immune system of macaque monkeys, a preferred model for the study of HIV disease in humans. This work involves nine macaques at the Oregon Regional Primate Centre and is evaluating the breadth and potency of the antibody as a means of strengthening immune system response to HIV infection. Under the direction of Dr. Sybille Muller, Vice President of Immpheron, Inc. based in Lexington, KY, which is the company's joint venture partner on the project, the current study is a follow up to an earlier study. In that study beneficial effects on the immune system of SHIV-infected macaques were reported and 1F7 normalized the immune response fighting the viral infection in the monkeys. Preliminary discussions have been held with the FDA on the production by Immpheron, Inc. of monoclonal antibody 1F7 for clinical trials in infected patients with 1F7 as an Investigational New Drug (IND). "signed" Victor J.E. Jones President THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE Immune Network Research Ltd. 900 - 475 Howe Street Vancouver, B.C., Canada V6C 2B3 Tel. (604) 689-3923; Fax. (604) 684-5854 www.stockgroup.com/imm.html (c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com old url (better for printing)